Nasofan

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nasofan

Understanding Nasofan

Nasofan is a medicinal nasal spray used for the localized treatment and prevention of inflammatory symptoms within the nasal passages. It belongs to a class of medications known as corticosteroids. Unlike systemic steroids taken in tablet form, this medication is applied directly to the lining of the nose to target inflammation at the source with minimal distribution throughout the rest of the body.

Therapeutic Purpose

The primary function of Nasofan is to reduce swelling and irritation in the nasal airways. It is most commonly used to manage symptoms associated with various forms of rhinitis, including:

  • Allergic Rhinitis: This includes seasonal allergies, such as hay fever caused by pollen, as well as perennial allergies triggered by dust mites, animal dander, or molds.
  • Vasomotor Rhinitis: Non-allergic nasal inflammation that results in congestion or a runny nose.

How It Works

The active ingredient in Nasofan works by inhibiting the release of natural substances in the body that cause an inflammatory response. When the nasal lining encounters allergens or irritants, the immune system typically reacts by causing redness, itching, and mucus production. Nasofan helps to stabilize this response, leading to a reduction in common symptoms such as:

  • Nasal congestion and stuffiness
  • Sneezing
  • Itching of the nose
  • Runny nose

Because of its mechanism of action, Nasofan is often used as a preventative measure. It is designed for regular use to maintain a consistent level of protection against inflammatory triggers, rather than providing immediate, short-term relief like a decongestant spray.

What side effects are possible with Nasofan?

Possible Side Effects and Safety Information

The safety profile for fluticasone propionate nasal spray is formally documented in regulatory labeling by government agencies, detailing classified adverse reactions and specific safety constraints. The section focuses strictly on these official safety findings.


Frequency-Classified Adverse Reactions

The adverse reactions are categorized based on official frequency reporting standards:

Frequency Examples of Adverse Reactions (Label-Documented)
Very Common (ge 1/10) Epistaxis (Nosebleeds)
Common (1/100 to <1/10) Headache, Nasal dryness, Nasal irritation, Throat irritation, Unpleasant smell/taste
Very Rare (<1/10,000) Nasal septal perforation, Glaucoma, Cataracts, Adrenal suppression, Growth retardation (children)
Not Known Nasal ulcers, Blurred vision, Dizziness, Somnolence

Systemic Risk and Special Safety Considerations

Adverse reactions are grouped by the official System-Organ Class (SOC). Very rare systemic effects include Hypercorticism and Adrenal Suppression (Endocrine Disorders), which are possible with prolonged, high-dose use. Severe Hypersensitivity Reactions, such as anaphylaxis and angioedema (Immune System Disorders), are also reported as very rare.

Ocular Events, including the development of Glaucoma and Cataracts, are documented as a very rare or long-term risk. Additionally, Localized Infections with Candida albicans in the nose and pharynx have been reported.

Population-Specific Notes: Growth monitoring is advised for pediatric patients due to the potential for growth rate reduction with long-term use. Caution is formally required in patients with severe hepatic impairment due to the potential for increased systemic exposure.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Nasofan (fluticasone propionate) overdose differentiates between single acute events and the established risk associated with chronic use above the recommended therapeutic dose.

Overdose Manifestations and Required Actions

Exposure Type Documented Risk and Manifestation Emergency Response Mandate
Acute Overdose Unlikely to cause acute systemic effects. Acute incidents generally require only medical observation and do not necessitate specific therapy. Seek medical help or contact a Poison Control Center right away for any suspected overdose event, as specified in regulatory labeling.
Chronic High Dose Risk of systemic corticosteroid effects from prolonged use, including Hypercorticism (Cushing’s features) and clinically significant Adrenal Suppression (HPA axis impairment). If signs of Adrenal Suppression occur, the medicine must be discontinued slowly under medical supervision to manage this serious risk.

Severe Outcome and Specific Considerations

The principal severe outcome of chronic high-dose exposure is Adrenal Suppression, which may necessitate supplemental corticosteroid administration during periods of stress or elective surgery. Monitoring of HPA axis function is a procedural requirement when systemic effects are suspected. Additionally, prolonged treatment with higher than recommended doses may cause growth retardation in children, a specific consideration documented in the official regulatory information.

Therapeutic Uses of Nasofan

What Nasofan Treats: Main Uses and Benefits

Relieving Symptoms of Allergic and Nonallergic Rhinitis

Nasofan is primarily used to provide supportive relief from the chronic and persistent symptoms of allergic rhinitis (hay fever) and nonallergic rhinitis. It is relevant for managing symptom clusters that may include pronounced nasal congestion (stuffiness), runny nose (rhinorrhea), frequent sneezing, and bothersome nasal itching. It is commonly used to support long-term stability of the nasal passages and contributes to improved day-to-day comfort.


Foundational Control for Chronic Nasal Inflammation

The medication plays a role in managing chronic symptoms and is commonly used as a maintenance treatment for long-lasting nasal conditions. It is applied during phases when patients experience moderate-to-severe symptoms year-round or during intense seasonal exposure, and may assist with associated symptoms like itchy and watery eyes. This therapy is used in clinical contexts to address the swelling associated with chronic rhinosinusitis and is relevant for easing the symptomatic burden associated with nasal polyps, providing supportive therapeutic benefit by supporting relief from obstruction and assisting with maintaining functional stability. The medication is commonly used to help manage allergic rhinitis, nonallergic rhinitis, and the symptomatic effects of nasal polyps.

“It supports the patient during difficult episodes by easing distress and helping to maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Relief for Persistent Congestion

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Nasofan (fluticasone propionate) is an aqueous nasal spray whose eligibility for use is defined by specific regulatory criteria relating to age, existing health conditions, and individual hypersensitivity.

Approved and Restricted Populations

Population Group Eligibility Status (Regulatory Basis)
Adults and Elderly Approved for use; no specific dose adjustment required for elderly patients.
Children Approved for those 4 years of age and older. Use is not recommended in children under 4 years (safety not established).
Hypersensitivity Contraindicated in patients with a known allergy to fluticasone propionate or any inactive ingredient.

Conditional Use and Comorbidities

Use of Nasofan requires special consideration in several clinical contexts, as specified in product labeling:

  • Nasal Trauma or Surgery: Use should be avoided until full healing has occurred in patients with recent nasal injury, surgery, or ulcers.
  • Existing Infections: Caution is warranted with certain infections, including ocular herpes simplex, untreated infections, or active/quiescent tuberculosis.
  • Pregnancy and Lactation: Use is restricted to instances where the potential benefit is determined to outweigh the potential risk to the fetus or infant, due to insufficient safety evidence in humans.
  • Eye Conditions: Close monitoring is advised for patients with a history of glaucoma or cataracts.

What should I know about interactions with other medicines?

The official regulatory profile for Nasofan (fluticasone propionate nasal spray) is structured around two primary interaction patterns: pharmacokinetic inhibition and additive pharmacodynamic effects.

Pharmacokinetic Inhibition and Restrictions

The most significant documented drug interaction is pharmacokinetic, involving substances that inhibit the Cytochrome P450 3A4 (CYP3A4) enzyme, which is the primary route for fluticasone propionate clearance. Strong CYP3A4 inhibitors, particularly the antiretroviral medicine Ritonavir, are explicitly addressed in regulatory labeling. Co-administration of Nasofan with Ritonavir is not recommended or is strictly prohibited by authorities. This severe interaction results from a substantial increase in the systemic plasma concentration (AUC) of fluticasone, which raises the risk of systemic corticosteroid effects. Other potent inhibitors like the antifungal Ketoconazole also increase fluticasone exposure and require caution.


Additive Effects and Population Notes

A separate interaction is classified as pharmacodynamic, where co-administration with other corticosteroids (nasal, inhaled, or oral) may lead to additive systemic glucocorticoid effects. The official documentation notes that due to the liver's metabolic role, the risk of increased systemic exposure and the potential for greater interaction severity may be heightened in patients with severe hepatic impairment. Official labels do not specify any mandatory timing separation requirements, and no specific interactions are documented with food, alcohol, or common herbal products.

Mechanism of Action

Core Genomic Action and Gene Expression

Fluticasone propionate acts as a highly selective agonist, binding to the intracellular Glucocorticoid Receptor (GR) in nasal cells. This drug-receptor complex moves into the cell nucleus, where it influences cellular programming through dual actions: transactivation (upregulating anti-inflammatory genes) and transrepression (suppressing pro-inflammatory genes, such as those governed by NF-κB). This genetic modulation suppresses the production of multiple inflammatory signals.


Pathway Suppression and Physiological Effects

The modulation of gene expression leads to a profound suppression of the inflammatory pathway, reducing the cellular synthesis and release of chemical mediators like cytokines, prostaglandins, and leukotrienes. This action also decreases the recruitment and activity of key inflammatory cells, such as eosinophils and mast cells, in the nasal lining. The anti-inflammatory actions produce local physiological changes, including a reduction in vascular permeability and localized vasoconstriction, which results in the reduction of mucosal edema.


Mechanistic Lag Time ⏱️

Because the fundamental mechanism relies on the relatively slow process of gene transcription and new protein synthesis (the genomic action), the full physiological effect develops gradually over several days of consistent pathway modulation.

Dosage and Administration Information

How Nasofan is Used (Fluticasone Propionate)

Nasofan is used exclusively via the intranasal route as an aqueous spray suspension, which delivers 50 micrograms (mcg) of fluticasone propionate per metered dose. The purpose of this topical route is to localize the medicine's effect directly to the nasal lining.

Adult and Adolescent Dosing Regimens

For adults and adolescents aged 12 and older, the initial dosing regimen is typically a 200 mcg total daily dose. This quantity is administered either as two measured sprays in each nostril once daily, or as one spray in each nostril twice daily. Once effective symptom control is achieved, the dose is generally reduced to the minimum effective level, often the maintenance dose of 100 mcg (one spray per nostril) once daily. The total daily intake should not exceed the 200 mcg maximum.

Administration Principles

The medicine is intended for regular, scheduled use and is often administered once daily, preferably in the morning. Consistent daily administration is critical because the full therapeutic effect may take 3 to 4 days to become apparent. Before the initial application or following any period of non-use (e.g., seven days or more), the pump must be primed by actuating it until a fine mist appears, ensuring a correct dose is delivered. During administration, the spray nozzle should be aimed away from the nasal septum.

Use in Pediatric Patients

For children aged 4 to 11 years, the initial recommended total daily dose is 100 mcg, administered as one spray in each nostril once daily. While this may be increased to 200 mcg if necessary, the 200 mcg level remains the maximum daily dose for this age group. The nasal spray is not recommended for children younger than four years.

Recent Clinical Evidence

Research evidence / Overview of studies for Nasofan


Evidence for use in Seasonal and Perennial Allergic Rhinitis

Research exploring the use of Nasofan (fluticasone propionate nasal spray) has focused primarily on conditions marked by fluctuating or episodic manifestations, specifically allergic rhinitis. The research for these conditions relies on numerous short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies examined outcomes related to physical discomfort, primarily by measuring the Total Nasal Symptom Score (TNSS), which combines patient ratings for core symptoms. Findings describe patterns observed in the studies where the measured symptom scores changed during the study period, typically 2 to 4 weeks, for the nasal spray compared to the placebo.

While research exploring short-term symptom changes is well-organized and extensive for both seasonal and year-round allergic rhinitis, long-term effects are not fully established. There is limited information for long-term outcomes, and comparative evidence is lacking in extensive, long-term, head-to-head studies against every alternative topical corticosteroid.


Evidence for use in Nonallergic Rhinitis and Nasal Polyps

Nasofan was studied for conditions where symptoms may vary in intensity, including perennial nonallergic rhinitis. The research base for this specific type consists of a smaller number of Randomized Controlled Trials, and the data reviewed has been complex because nonallergic rhinitis includes many different underlying factors. The follow-up durations were limited, typically only about 28 days.

Fluticasone propionate was also evaluated in studies focusing on Chronic Rhinosinusitis with Nasal Polyps. These studies observed patients with conditions marked by functional limitations, and the primary objective outcome that researchers measured was the change in the size and grade of the polyps using a specific Polyp Score. A limitation is that a significant part of the research has explored specialized, non-standard delivery methods rather than the standard nasal spray formulation.

Key Studies & References

  1. Fluticasone Propionate Nasal Spray, USP, 50 MCG - DailyMed
  2. Fluticasone (nasal route) - MedlinePlus Drug Information

Frequently Asked Questions (FAQ)

Common questions about Nasofan (FAQ)

Q: How is Nasofan different from an oral antihistamine tablet?

Nasofan is a topical corticosteroid designed to work locally by controlling chronic inflammation inside the nose. Unlike an oral antihistamine, which works throughout the body to block a chemical, Nasofan’s primary purpose is to be a preventative maintenance treatment for swelling and irritation over time. This local action allows for foundational relief.

Q: What is the difference between Nasofan and other fluticasone sprays like Flonase?

Nasofan and other fluticasone propionate nasal sprays of the same strength are generally viewed as therapeutically equivalent by regulatory bodies. While the active ingredient is the same, differences may exist in the inactive ingredients or the design of the spray device itself, and a review of individual product information may be helpful.

Q: What does it mean when official documents mention the risk of 'adrenal suppression'?

Official product information describes adrenal suppression as a rare, serious systemic effect, typically seen with prolonged high-dose use. This term refers to the reduction of the body’s natural cortisol production by the adrenal glands due to the presence of the external corticosteroid. This may affect the body’s natural cortisol regulation.

Q: Can Nasofan be used for treating symptoms caused by a common cold?

According to official regulatory documents, Nasofan is approved for the management of chronic conditions such as allergic and non-allergic rhinitis and nasal polyps. It is not approved as a treatment for the acute, short-term symptoms caused by a common cold.

Q: What should be done if Nasofan doesn't seem to be helping after a few weeks?

The full beneficial effects of Nasofan usually become apparent after several days to a few weeks of consistent daily use. Official regulatory labels state that if symptoms do not improve or if they worsen after this period, consultation with a healthcare provider for further review may be appropriate.

Q: Is it recommended to start Nasofan before allergy season begins?

Because the medication works as a preventative maintenance treatment and takes several days (typically 3 to 4 days) to build up its full anti-inflammatory effect, starting Nasofan a few days to a week before expected seasonal exposure is a pattern aligned with the drug’s mechanism.

Q: What happens if I stop using Nasofan suddenly?

Stopping the medication suddenly after using it for a long period at a high dose may carry risks related to potential systemic effects, such as adrenal suppression. Regulatory documents indicate that consultation with a healthcare provider is appropriate before making any changes to usage, including dose reduction or cessation.

Q: Does Nasofan have the potential to cause feelings of anxiety or mood changes?

Due to the potential for rare systemic absorption of the corticosteroid, official documents note that changes in mood, including anxiety, are a reported effect for this class of medicine. This is a potential rare side effect that should be reviewed in the full safety information.

Q: What is the official information regarding weight gain while using Nasofan?

Regulatory documents list weight increase as a less common adverse reaction. This is usually associated with the potential for systemic corticosteroid effects, which can occur with high-dose or prolonged use. Changes in weight, if experienced, are typically discussed with a healthcare provider.

Q: Can Nasofan be used at the same time as other nasal products like decongestant sprays?

The product information focuses warnings on other corticosteroids and specific enzyme inhibitors. Although specific interactions with common non-steroid decongestant sprays are not typically listed as contraindications, consultation with a healthcare provider is the standard approach before combining nasal products.

Q: Does Nasofan affect the effectiveness of birth control pills?

Specific interaction data between fluticasone propionate nasal spray and oral contraceptives is not usually published in regulatory sections. This lack of specific warning suggests that the systemic exposure from the nasal spray is generally considered too low to warrant a caution in this regard.

Q: What should a user do if they accidentally miss a dose of Nasofan?

If a dose is missed, it is typically taken as soon as remembered, unless it is almost time for the next scheduled dose. Regulatory information indicates that if the next dose is due soon, the missed dose is typically skipped. A double dose is not recommended to compensate for a missed dose.

Q: What is the recommended method for cleaning the Nasofan spray applicator?

To maintain a clear and functional spray, the product information states the applicator should be cleaned at least once a week. This is done by removing the nozzle and cap, washing them under warm running water, allowing them to air dry completely, and then carefully reassembling the unit.

How should Nasofan be stored and disposed of?

How to Store and Dispose of Nasofan

The storage and disposal of Nasofan Aqueous Nasal Spray must adhere strictly to official regulatory conditions to maintain product stability and safety.


Storage Requirements

Detail Official Regulatory Requirement
Temperature Store between 4°C and 30°C (39°F and 86°F), or below 25°C.
Protection Do not freeze. Keep away from excess heat, moisture, and light.
Child Safety Keep out of the sight and reach of children.
Stability The unit must be discarded after the labeled number of sprays (e.g., 120 actuations) has been used. Do not use past the expiration date.

Disposal Instructions

Official disposal guidance states that the nasal spray must not be thrown away via household waste or wastewater. Unused or expired medication should be returned to a pharmacist or disposed of in accordance with local environmental requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nasofan found in:

A-Z Index: